3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Q3 FY2022 Earnings Presentation
31 slides from 3b Blackbio Dx's earnings presentation, Feb 9, 2022
Slide 1: Cover letter to BSE - Investor Presentation
KILPEST INDIA LIMITED Kilpes REGD. OFFICE&FACTORY 7C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL 462 023 INDIA URE O0AL CERAON Tel 91-755 2586536, 2586537 E-mall: kilpest@bsnl.in Visit us at www.kilpest.com kilpestbpl@yahoo.co.in CIN:124211MP1972PLC001131 February 9, 2022 The Relationship Manager, Departme
Slide 2: Investor Presentation February 2022
Farmer’s Trusted Agro-Input Partner for 49 Years Reliable and Affordable Healthcare Diagnostic Solutions INVESTOR PRESENTATION FEBRUARY, 2022
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Financial Performance and Key Highlights
FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS
Slide 5: Performance Highlights – Q3 2021-22
Performance Highlights – Q3 2021-22 KILPEST (Consolidated) Q3 FY22 Q3 FY21 4269.44 2628.30 Q3 2021 Net Sales 1435.88 4269.44 Q3 2022 Profit Before tax 830.97 2628.30 1435.88 830.97 Profit After tax 656.12 1966.87 Paid-Up Equity Share Capital 750.81 750.81 Reserves 12455.98 1636.39 Revenue PBT Earnin
Slide 6: We Are Proud To Be A Part Of
WE ARE PROUD TO BE A PART OF minha BEST: 3 2021
Slide 7: Key Highlights - Agrochemicals
Key Highlights - Agrochemicals Impact of COVID-19 There was a potential loss in the production/sales during the Q3 of FY22. The sales for the Q3 remain static for agrochemicals. Company continues to focus on Public Health/Warehousing sector and Exports. As due to COVID-19, Private agriculture
Slide 8: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health &
Slide 9: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 10: Introduction – 3B BlackBio Biotech India Limited
Introduction – 3B BlackBio Biotech India Limited “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, embarked on its mission in 2011 with a vision to provide reliable, accurate and affordable healthcare solutions to all. Ever since its inception, 3B BlackBio is engaged in Des
Slide 11: TRUPCR® from 3B BlackBio Biotech (I) Ltd.
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Our Vision: Our Mission: To offer reliable, affordable and To design and develop molecular effective healthcare solutions to all by diagnostics products of superior quality recognizing the great potential of and value that continuously improves biotechnology
Slide 12: Timeline & Milestones
Timeline & Milestones COVID-19 YEAR GONE GLOBAL TRUPCR® Launch of SARS-CoV- Launch of Oncology 2 Launch Panels MANCHESTER of Solid qPCR Extending Tumor AML Menu with SITE Virology & Kit ALL Public EGFR Health (USFDA- Adding MPN KRAS EUA) Virology Entering & HBV, HCV Launch of Oncology Expanding Geno
Slide 13: Growth Canvas
Growth Canvas ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Financial Highlights – Q3 FY 2021-22
Financial Highlights – Q3 FY 2021-22 3986.86 2572.85 835.25 1197.05 Revenue Q3 2021 EBITDA 2554.85 Q3 2022 1907.55 827.75 643.89 PBT PAT Rs. In Lakhs. * The figures of Year 2020-21 cannot be compared due to COVID-19 which was a one-time happening ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HE
Slide 15: Business Outlook – Post COVID
Business Outlook – Post COVID Due to COVID-19, nationally and internationally, number of Molecular Diagnostics Labs and manufacturers have increased manifolds, but with COVID-19 infections potentially decreasing after June 2021, a lot of labs might shut down due to non-viability, still there would b
Slide 16: Manchester Project
Manchester Project In line with the company's vision for expansion into the European market, 3B has signed a joint venture agreement in November 2021 with its primary European distributor, Manchester based, HS Biolabs Ltd, which is being re-established as “TRUPCR Europe Limited”. TRUPCR Europe Limit
Slide 17: MEDLAB DUBAI 2022
MEDLAB DUBAI 2022 The company participated in Medlab Middle-East 2022 held in Dubai during 24-27 January 2022. There was a lot of interest from various end-users and prospective partners for our products. With the export restrictions now removed, we are expecting a growth in the international market
Slide 18: Utilization of Funds, Scheme of Amalgamation, Proposed NSE Listing
Utilization of Funds We are looking for options to acquire a company in similar business area to get inorganic growth in FY22 and onwards. We will only go for the acquisition if it makes financial sense and meets our internal IRR criteria. We would also be looking at share buyback in FY22/23 if we a
Slide 19: Rapid Antigen Vertical, Expansion and NGS Vertical
Rapid Antigen Business Vertical We are pleased to announce that with continuous and extensive efforts, the company has finally got the approval of “TRURAPID® COVID-19 Ag Test” from ICMR (Indian Council of Medical Research) on February 2, 2022. Now we will try to build this product assuming that COVI
Slide 20: Exports
Exports This year we want to focus on exports. Our products have been well-accepted in more than 25 countries. With the export restriction now removed, we have fast paced our marketing strategy for the international customers. We are in discussion with many key customers internationally and hope tha
Slide 21: R&D and People
R&D R&D People •Highly educated team of scientist from varied backgrounds •Dedicated teams for respective segments •Separate onco team headed by researchers (Ph.Ds.) from oncology background •Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 22: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 23: Our Certificates
Our Certificates US FDA EUA COVID-19 Award of RT-PCR Kit Excellence For Leading CDSCO Licensed IVD Company Diagnostic Kits of the year 2020-21 ISO 13485:2016 Certified Company ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 24: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Mass Spec Hybridization Sanger Sequencing Next Generation Sequencing Low Volume Microarray ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 25: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 26: All Inclusive TRUPCR® Products
All Inclusive TRUPCR® Products TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis Sample stabilization TRUPCR ® Nu
Slide 27: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 28: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 29: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 30: Outstanding Achievement Award for Excellence in R&D by FMPCCI
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 31: Jai Hind
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS